ATTO (Attovia Therapeutics) Short-Term Debt: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATTO Attovia Therapeutics Inc ATTO
8 GF Score
Price $20.38
View Full Analysis

What is Attovia Therapeutics Short-Term Debt?

Attovia Therapeutics ATTO -6.94% 8 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates ATTO with a GF Score™ of 8/100.

Attovia Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Attovia Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Attovia Therapeutics Short-Term Debt Related Terms

Attovia Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Attovia Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Attovia Therapeutics Short-Term Debt Chart

Attovia Therapeutics Annual Data
Trend Dec24 Dec25
Short-Term Debt
0.00 0.00

Attovia Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Short-Term Debt 0.00 0.00 0.00 0.00
ATTO
8GF Score
Attovia Therapeutics Inc ATTO
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Attovia Therapeutics (ATTO) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Attovia Therapeutics' Short-Term Debt too high?
Attovia Therapeutics' current Short-Term Debt is $0.00 Mil. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' Short-Term Debt compare to ?
Attovia Therapeutics' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Attovia Therapeutics's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Attovia Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Attovia Therapeutics Business Description

Comparable Companies
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score

Get the complete analysis for ATTO

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.38
Price